Results 211 to 220 of about 362,216 (339)

Duration of sodium zirconium cyclosilicate treatment and continuation of RAASi therapy after a hyperkalaemia episode

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renin–angiotensin–aldosterone system inhibitors (RAASi) are foundational in the management of heart failure (HF) and chronic kidney disease (CKD) but increase the risk of hyperkalaemia. To facilitate continuation of RAASi therapy, guidelines suggest managing hyperkalaemia using newer potassium binders such as sodium zirconium ...
Charles V. Pollack Jr.   +9 more
wiley   +1 more source

Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry)

open access: yesESC Heart Failure, EarlyView.
Abstract Aims The last released European guidelines on the management of heart failure (HF) recommend in patients with chronic HF with reduced ejection fraction (HFrEF) a pharmacological approach based on four fundamental drugs to be rapidly implemented and then uptitrated to modify disease progression.
Stefania Paolillo   +62 more
wiley   +1 more source

Crosstalk between renin and arachidonic acid (and its metabolites). [PDF]

open access: yesLipids Health Dis
Das UN   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy